Of all the cancers at the center of the Roundup litigation, follicular lymphoma is the one most likely to be misunderstood by the person who has it. It rarely arrives as an emergency. Many people learn they have it almost by accident, after a scan or a swollen lymph node leads to a biopsy, and are then told the plan is to watch it. A cancer that no one is rushing to treat does not feel like the kind of thing that belongs in a lawsuit. But follicular lymphoma is a non-Hodgkin lymphoma, it is a B-cell cancer, and it is one of the subtypes for which the connection to glyphosate has been most specific in the scientific literature. Understanding why starts with understanding the disease.
What Follicular Lymphoma Is, and Why “Slow-Growing” Trips People Up
Follicular lymphoma is a cancer of B lymphocytes, the white blood cells that normally produce antibodies. It is the second most common form of non-Hodgkin lymphoma, accounting for roughly one in five lymphoma diagnoses in Western countries, and it is the most common of the indolent, or slow-growing, lymphomas. The median age at diagnosis is about 65. The name comes from the way the cancerous cells cluster into follicle-like patterns in the lymph nodes, a pattern a pathologist identifies under the microscope.
Because it is indolent, follicular lymphoma is frequently managed at first with active surveillance — the strategy oncologists call “watch and wait.” For a patient without symptoms and with a low tumor burden, studies have found that starting chemotherapy immediately does not reliably extend life compared with careful monitoring, so treatment is deferred until the disease progresses. That is standard, evidence-based oncology. It is also the source of the first misconception: people reasonably assume that if the cancer were serious, someone would be treating it. In fact, the opposite framing is closer to the truth. Watch and wait is used because follicular lymphoma is a chronic, generally incurable disease that most people live with for many years — median survival now stretches toward two decades with modern antibody therapies such as rituximab — not because it is trivial.
The Evidence Linking Follicular Lymphoma to Glyphosate
The foundation for the entire Roundup litigation is the World Health Organization's International Agency for Research on Cancer (IARC), which in 2015 classified glyphosate as “probably carcinogenic to humans” (Group 2A). That classification rested largely on the human evidence for non-Hodgkin lymphoma, supported by clear evidence of cancer in animals and by mechanistic findings. We walk through the regulatory dispute behind that conclusion in our explainer on why IARC and the EPA reached opposite conclusions.
What matters for this article is that the signal has not been generic. In the pooled epidemiology, follicular lymphoma keeps surfacing as one of the subtypes most specifically associated with glyphosate exposure. A widely cited scientific review by pathologist Dr. Dennis Weisenburger, published in Clinical Lymphoma, Myeloma & Leukemia in 2021, synthesized the case-control and cohort data and noted that even analyses that found no overall increase in non-Hodgkin lymphoma still highlighted an association for follicular lymphoma in particular.
A more recent Italian multicenter case-control study, published in the journal Environmental Health in 2021, is the most pointed example. Among workers classified as occupationally exposed to glyphosate, the study reported markedly elevated odds ratios for follicular lymphoma specifically — higher among those with greater exposure intensity and longer exposure duration. Case-control odds ratios are not the same thing as proof of causation, and the confidence intervals in exposure studies are wide, so no single study decides anything for an individual. But the pattern is consistent with what IARC concluded and with the mechanistic picture below: when researchers look at glyphosate and lymphoma by subtype, follicular lymphoma is repeatedly one of the names that comes up.
The B-Cell Mechanism: Why the Signal Falls Where It Does
This is the part of the story that is easy to miss and that makes follicular lymphoma a particularly clean fit for the science. Follicular lymphoma is not just any cancer; it has a defining genetic signature. The overwhelming majority of cases carry a specific chromosomal translocation known as t(14;18), which fuses the BCL2 gene next to an antibody (immunoglobulin) gene. The practical effect is that BCL2, a gene that blocks cell death, gets switched permanently “on” in the B cell, so cells that should die instead survive and accumulate. That translocation is the biological hallmark of the disease.
Where does a translocation like t(14;18) come from? It is understood to arise from mistakes in the genome-editing machinery that B cells use on purpose to build and refine antibodies — a normally tightly controlled process that cuts and rearranges DNA. IARC found strong evidence that glyphosate is genotoxic (it damages DNA) and that it induces oxidative stress in cells. And review authors have gone a step further and proposed a subtype-specific pathway: glyphosate appears able to upregulate an enzyme called activation-induced cytidine deaminase (AID), one of the central tools in that same B-cell editing machinery. Overactive AID is a recognized driver of the kind of DNA breaks and translocations that produce B-cell lymphomas.
Put those pieces together and there is a coherent biological reason the epidemiologic signal lands on B-cell cancers like follicular lymphoma rather than scattering randomly: a chemical that damages DNA and revs up the B cell's own genome-editing enzymes is acting precisely where follicular lymphoma is born. This is emerging, mechanistic science, not a verdict about any one person's tumor. But it is exactly the kind of “how would this even happen” question that a well-built case has to be able to answer, and follicular lymphoma answers it unusually well.
A Medical-Legal Read on the “Watch and Wait” Case
At our firm, Herb Borroto, M.D., J.D., our Medical-Legal Expert, reads the pathology reports, the flow cytometry, and the immunohistochemistry himself before a case is evaluated, precisely because subtypes like follicular lymphoma turn on details a purely legal review would miss — the grade, the presence of the t(14;18) marker, whether there has been transformation to a more aggressive lymphoma. That medical read matters here for two practical reasons.
First, a follicular lymphoma diagnosis is a diagnosis whether or not treatment has begun. The pathology confirms it; the oncologist's decision to watch rather than treat is a separate clinical judgment about timing. A person on active surveillance has the same underlying diagnosis as a person receiving chemotherapy. Second, follicular lymphoma's slow, quiet course is exactly what produces long gaps between Roundup exposure and diagnosis, and those gaps raise timing questions that people tend to get wrong. Alex Alvarez, our Managing Partner and a Board Certified Civil Trial Lawyer, evaluates which legal theory an exposure history can support and how the filing deadline applies — questions that, in most states, turn on a discovery rule rather than the date of last exposure. We cover that timing issue in detail in can I still sue Monsanto over Roundup in 2026.
Where Follicular Lymphoma Fits After Durnell
The legal landscape shifted in 2026. In Monsanto Co. v. Durnell, decided June 25, 2026, the Supreme Court held 7-2 that federal law preempts state-law failure-to-warn claims where the EPA approved a pesticide label without a cancer warning. That narrowed one road. It did not touch the road The Alvarez Law Firm has always led with: strict product liability based on design defect, the argument that the product was unreasonably dangerous as formulated, independent of any label or any agency finding.
Follicular lymphoma sits comfortably on that surviving road. A design-defect theory does not ask whether the EPA required a warning; it asks whether the formulation itself, and what the manufacturer knew about it, made the product unreasonably dangerous to the people who used it as intended. The scientific case for that argument — genotoxicity, oxidative stress, and a B-cell-specific mechanism that fits follicular lymphoma's biology — does not depend on the government's say-so at all. If anything, the sharper the subtype-specific evidence, the more directly it speaks to the design-defect question.
What This Means If You Were Diagnosed With Follicular Lymphoma
A few practical takeaways:
- Being on “watch and wait” does not remove a diagnosis. Active surveillance is a mainstream treatment strategy for indolent follicular lymphoma, not a sign that the cancer does not count.
- An old exposure does not automatically mean it is too late. Follicular lymphoma is frequently diagnosed years after exposure, and most states start the filing clock under a discovery rule. Deadlines vary by state and are fact-specific, so the timeline is worth having reviewed rather than assumed.
- Follicular lymphoma is squarely within the qualifying diagnoses. It is a non-Hodgkin lymphoma and a B-cell lymphoma, and it appears repeatedly in the subtype-specific evidence. Our overview of which NHL subtypes qualify puts it in context.
- The pathology is the foundation. A biopsy-confirmed diagnosis together with a documented exposure history is what any surviving legal theory is built on. Our guide to who qualifies for a Roundup lawsuit walks through what we look at.
None of this is a prediction about any particular case, and nothing here is a promise of any result. Whether a specific case can move forward depends on the diagnosis, the exposure record, and the law of the state where the case belongs, evaluated on the individual facts.
Frequently Asked Questions
Is follicular lymphoma linked to Roundup and glyphosate?
Follicular lymphoma is a subtype of non-Hodgkin lymphoma, and non-Hodgkin lymphoma is the cancer at the center of the Roundup litigation. It is also one of the subtypes for which the epidemiologic signal has been most specific. The World Health Organization's IARC classified glyphosate as probably carcinogenic to humans (Group 2A) in 2015, based largely on non-Hodgkin lymphoma. Case-control research, including an Italian multicenter study published in Environmental Health in 2021, has reported elevated odds ratios for follicular lymphoma specifically among people classified as glyphosate-exposed. None of that decides an individual case, which depends on the diagnosis, the exposure history, and the law of the relevant state.
My follicular lymphoma is being watched, not treated. Can I still have a claim?
Follicular lymphoma is often managed with active surveillance, sometimes called watch and wait, because it is slow-growing and starting chemotherapy early does not always help. Being on observation does not mean you do not have a diagnosis. A biopsy-confirmed follicular lymphoma is a confirmed non-Hodgkin lymphoma regardless of whether treatment has started. The treatment plan your oncologist chooses is a medical decision; whether a case can move forward is a separate legal question that turns on diagnosis, documented exposure, and the applicable statute of limitations.
I used Roundup years ago and was only recently diagnosed. Is it too late?
A long gap between exposure and diagnosis is common with follicular lymphoma, which is indolent and frequently found years or decades after exposure. In most states the filing clock is governed by a discovery rule, meaning it often begins to run when a person knew or reasonably should have known that a diagnosis may be connected to an exposure, not on the last day someone sprayed. Deadlines vary significantly by state and the analysis is fact-specific, so the safe course is to have the timeline reviewed rather than to assume the window has closed.
Why do researchers connect glyphosate specifically to B-cell lymphomas like follicular lymphoma?
Follicular lymphoma is a B-cell cancer defined by a signature chromosomal translocation, t(14;18), that places the BCL2 gene under the control of an antibody gene and blocks the normal death of the B cell. That translocation is understood to arise from errors in the genome-editing machinery B cells use to build antibodies. IARC found strong evidence that glyphosate is genotoxic and induces oxidative stress, and review authors have proposed that glyphosate can upregulate activation-induced cytidine deaminase (AID), an enzyme central to that same B-cell machinery. That proposed pathway offers a biological reason the signal would fall on B-cell lymphomas. It is mechanistic and emerging evidence, not proof about any one person's cancer.
Bottom Line
Follicular lymphoma confounds expectations. It is slow, it is often watched rather than treated, and it tends to surface long after the exposure that may have contributed to it — a combination that leads people to assume it is either too minor to matter or too old to act on. Neither assumption holds up. It is the second most common non-Hodgkin lymphoma, it carries a B-cell genetic signature that fits the proposed biology of how glyphosate damages cells, and it appears again and again when researchers break the epidemiology down by subtype. The indolent course is a reason to have the facts reviewed sooner, not later, because filing deadlines run on their own clock regardless of how the cancer behaves.
At our firm, Herb Borroto, M.D., J.D., our Medical-Legal Expert, reads the pathology and the immunohistochemistry himself, and Alex Alvarez, Managing Partner and Board Certified Civil Trial Lawyer, evaluates which legal theory the exposure history can support. If you or a family member used Roundup and were later diagnosed with follicular lymphoma or another form of Non-Hodgkin Lymphoma, B-cell Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma, the free case review is exactly what it says: no obligation, and no fee unless we recover for you.